Stock Forecast

  Icosavax, Inc. ( ICVX) Stock. Should you Buy or Sell?    $ 4.77

0.12 (2.45 %)

Icosavax, Inc. Analysis

Updated on 10-09-2022
Symbol ICVX
Price $4.77
Beta 0.000
Volume Avg. $201.61 thousand
Market Cap $190.25 M
52 Week Range $4.0 - $41.98

Icosavax, Inc. opened the day at $4.77 which is +'2.45 % on yesterday's close. Icosavax, Inc. has a 52 week high of $41.98 and 52 week low of $4.0, which is a difference of $37.98. We like to see positive, upward trending shares, preferably with momentum. Market capitalization is $190.25 M and total net profit is $0 which means the company is trading at inf times profit to market capitalization. Theoretically, if you were to buy Icosavax, Inc. for $190.25 M, it would take 15 years to get your money back. Icosavax, Inc. are in the Biotechnology space which will have a sweet spot and industry standard for net profit multiples.

Price Chart

1 D | All


Icosavax, Inc. Stock Forecast - Is Icosavax, Inc. a Buy or Sell?

DCF ScoreStrong Buy
ROE ScoreNeutral
ROA ScoreNeutral
DE ScoreNeutral
PE ScoreSell
PB ScoreBuy
Overall RecommendationBuy

Growth and Value

PE Ratio 47.700
Dividend Yiel 0.000
Net Profit Margin -25.270

Valuing Icosavax, Inc.

Price Book Value Ratio 0.779 Price To Book Ratio 0.779
Price To Sales Ratio 103.374 Price Earnings Ratio -4.091

How liquid is Icosavax, Inc.

Current Ratio 20.891
Quick Ratio 20.412


Debt Ratio 0.066 Debt Equity Ratio 0.071
Long Term Debt To Capitalization 0.021 Total Debt To Capitalization 0.025

Latest news about Icosavax, Inc.

Icosavax, Inc. (ICVX) Reports Q2 Loss, Lags Revenue Estimates

Icosavax, Inc. (ICVX) delivered earnings and revenue surprises of -3.64% and 100%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Date : 15/08/2022

Why Icosavax Stock Is Soaring Today

The company's Q4 update made investors feel a little better after receiving disappointing news last week.

Date : 31/03/2022

Why Icosavax's Shares Are Trading Lower Today

Icosavax Inc (NASDAQ: ICVX) has announced topline interim results from its ongoing Phase 1/2 trial of IVX-411, a VLP vaccine candidate displaying the SARS-CoV-2 receptor-binding domain (RBD). In the naïve setting, adjuvant effect on immunogenicity and a dose-response were.

Date : 25/03/2022

Icosavax to Participate in Upcoming Investor Conferences

SEATTLE, Nov. 11, 2021 (GLOBE NEWSWIRE) -- Icosavax, Inc. (NASDAQ: ICVX), a biopharmaceutical company leveraging its innovative virus-like particle (VLP) platform technology to develop vaccines against infectious diseases, with an initial focus on life-threatening respiratory diseases, today announced that Adam Simpson, Chief Executive Officer of Icosavax, will participate in two upcoming investor conferences.

Date : 11/11/2021

Icosavax co-founder and UW researcher Neil King talks vaccine development in the ‘digital era'

We are now in the “digital era” of vaccine development, University of Washington researcher Neil King said at the GeekWire Summit in Seattle on Tuesday.

Date : 06/10/2021

About Icosavax, Inc.

Sector : Healthcare
Industry : Biotechnology

Website :

Exchange : NASDAQ Global Select

Description :

Icosavax, Inc., a biopharmaceutical company, develops vaccines against infectious diseases. The company, with the help of its virus-like particle (VLP) platform technology, focuses primarily on life-threatening respiratory diseases. Its products in pipeline include IVX-121, a vaccine candidate with RSV target and is under Phase 1/1b clinical trial; IVX-A12, a respiratory syncytial virus (RSV) monovalent antigen candidate with RSV/human metapneumovirus (hMPV) bivalent target indication; IVX-241, a vaccine candidate with hMPV target; and IVX-411, an original receptor binding domain (RBD) sequence antigen with SARS-CoV-2 target indication and is under Phase 1/2 clinical trial. The company was incorporated in 2017 and is headquartered in Seattle, Washington.

My Newsletter

Sign Up For Updates & Newsletters